European Union - English - EMA (European Medicines Agency)

serono europe limited - efalizumab - psoriasis - immunosuppressants - treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and puva (see section 5.1 - clinical efficacy).

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - efalizumab - powder and solvent for solution for injection - 125mg